Spanish healthcare data analysis firm Sequentia Biotech has secured €10m in funding to drive its software designed to advance the fields of genomics, transcriptomics, epigenomics and microbiomics with funding from the European Union (EU).
The money was primarily led by French venture capital company Seventure Partners, with additional investment coming from the European Innovation Council (EIC) Fund, the European Commission’s initiative dedicated to accelerating start-ups across the continent.
The funds will allow Sequentia to accelerate to market its software designed to examine the microbiome of patients and translate its findings into actionable steps for clinicians or as part of personalised medicine systems. The company says that beyond healthcare its MICK software may also find use in the fields of biomedicine and agri-tech.
Walter Sanseverino, CEO of Sequentia Biotech, said: "We are delighted to announce this fundraising and our backing by Seventure Partners and the EIC Fund, two highly renowned venture capital investors with strong track records in supporting innovative companies in the life sciences sector. This investment will play a major role in advancing our mission to unlock the full potential of omics and accelerate the adoption of MICK by researchers and healthcare professionals globally."
The EIC fund comes as the agency is looking to fill gaps in its funding, and invest in supporting companies in the development and commercialisation of what it calls disruptive technologies with the cooperation of private investment groups.
Riccardo Aiese Cigliano, scientific director for Sequentia Biotech, said: "We believe, we are on the brink of a new era in omics research and in our view, this investment is a signal of the market's confidence in our vision and MICK's potential to disrupt the status quo. Our MICK platform offers a major step forward across multiple health applications, from precision nutrition and wellness to understanding biological processes and diseases, to creating microbiome-based treatments and therapies.”
Elsewhere across the EU, the EIC has similarly invested in Endoron Medical’s flagship product, the catheter-based EndoStapling solution Aortoseal. Similarly, Cardiology start-up Acorai has secured $4.5m in an oversubscribed round to advance its non-invasive intracardiac pressure monitoring device, with further funding from the EIC.
